TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: blood loss during hepatectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe use of GH
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet reactivity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Relative Change in Percentage of Liver Fat Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in myocardial T2* magnetic resonance signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: urinary iodine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: free triiodothyronine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: free thyroxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ocular Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seven days mortality
Endpoint domain: Mortality/survival
Primary endpoint: Local inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Near Complete Response (nCR)/ Complete Response (CR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of glutathione/glutathione disulfide (GSH/GSSG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of cysteine/cysteine disulfide (Cys/CysSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Electrical potential of glutathione/glutathione disulfide (GSH/GSSG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Electrical potential of cysteine/cysteine disulfide (Cys/CysSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Timed get up and go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Jaw mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cognitive Control of Emotion (CCE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diffusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-attribution (externalizing bias score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in state self-esteem score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in eating disorder symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients without virological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Severity and Symptoms Via Self-report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PTSD Severity and Symptoms Via Clinician Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of the SARC-F questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the SARC-F questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall concordance agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pruritus
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incremental Cost per QALY gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of the Pulse-Hemoglobin-Meter Monitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: requirement for endotracheal intubation with mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of hypoxemia episodes (Sp02<90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of hypoxemia episodes (Sp02<95%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in Number of Incontinent Episodes Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with progression in radiation field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant's Subjective Rating of Dryness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant's Subjective Rating of Foreign Body Sensation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of digital image-processing techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportions of participants with normal Hb1Ac
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance of SFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral ventricles width after delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean latency of the P300 component of ERPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in breast fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Optic nerve head vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACE2 level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Active T2 Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Using time of hemofilters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes in outflow facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean Change in Liver Fat Content Based on Elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percent Change in Liver Fat Content Based on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in Serum Concentrations of Very Low Density Lipoprotein-triglycerides (VLDL-TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in AUC of Serum Very Low Density Lipoprotein-triglycerides (VLDL-TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in food-related quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Quality of Life (QOL) Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Bleeding at the HD Vascular Access Site
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of ctHPV-DNA as a biomarker for recurrent disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of cough within 5 minutes post dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in maximum fall in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in hard exudates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant stability measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgically complete resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average percent deviations from the assigned eating system score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass balance data of excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of SHR6390 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of main metabolite and biotransformation pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients suffering treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ovarian microvascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosocial Intervening Behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Anaerobic Cardiovascular Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Life (QoL) related response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptom spectrum and severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Infarct Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the serum NN1218 concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circadian regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarkers of the skin lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in patient symptoms over time using pruritis VAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in lesion size over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in patient SCORAD scale score over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentages of Subjects With Persisting Serum Bactericidal Titers ≥1:5 and ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Persisting Antibody Titers in Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Ratios (GMRs) in Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accidental non-fatal overdose in the past month
Endpoint domain: Adverse events/effects
Primary endpoint: Share of participants with SARS-CoV-2 detectable in PCR
Endpoint domain: Adverse events/effects
Primary endpoint: therapeutic efficacy after FMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Eye Symptoms Score Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall procedure and imaging test ordering rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Choosing Wisely-based clinically inappropriate ordering rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HEDIS-based clinically appropriate ordering rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetics and Pharmacodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of Diaper Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: appropriateness of prescriptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brain-computer interface stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration [Cmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve [AUC0-last]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anaerobic threshold (AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal oxygen uptake (VO2Max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Blood Pressure (BP) Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weighted Mean (Area Under Effect Curve [AUEC]) Blood Pressure Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentrations of indoor allergens and lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Categorization Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of T cells (CD3+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Caloric Weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SHA Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cVEMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SHA Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: oVEMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Methamphetamine withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scoliosis curve magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total nasal symptoms score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in magnetic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Any Respiratory Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Overall Response Score (ORS) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IgG, IgA and IgM level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Coefficient of correlation between inter-regional hemodynamic signals and clinical data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of correlation between inter-regional hemodynamic signals and neuropsychological data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of linear scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Leg ulcer recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the serum insulin concentration curve within 24 hours (INS-AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Best Confirmed Complete Cytogenetic Response (cCCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum rituximab levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional and structural changes in the cardiovascular system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VO2 evaluation after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Achieving at Least 50% of Total Pain Relief Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic suppression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average difference in luteinizing hormone (LH) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post-ERCP pancreatitis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in teacher-children relationship quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Performance on an emotion sensitivity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on a facial emotion morphing task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of geographic atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Percentage of improvement in clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose and lipid metabolism disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with Severe Ovarian Hyperstimulation Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Each Category of Adverse Events in Stage I
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants in Each Category of Adverse Events in Stage II
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Differentially Expressed Genes at p < 0.05
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Significantly Differentially Expressed Genes at FDR < 0.05
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Inotuzumab Ozogamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Vaccine Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in stone size (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement level between capsule and colonoscopy in classifying colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Attendance to Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Toxicity Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Attention Deficit Hyperactivity Disorder- Rating Scale (ADHS-RS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employee purchases of healthy items
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to CPAP Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Rates of Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization Success of Maxillary Sinus Anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visualization Success of Frontal Sinus Anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visualization Success of Sphenoid Sinus Anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Symptomatic PCR-Confirmed Primary C. Difficile Infection Cases
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacodynamic (Biomarkers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic (Histology)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic (Immunohistochemistry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative opioid requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta-cell autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dose Limiting Toxicity or Maximum Tolerated Dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-related adverse events as assessed by CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline on oxidation stress biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants Who Discontinued Treatment Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Tovaxin TCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Tovaxin TCV
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of Tovaxin TCV
Endpoint domain: Adverse events/effects
Primary endpoint: Limb circumference at 10 cm above the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in muscle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle Protein Synthesis (MPS) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of infants developing omphalitis
Endpoint domain: Adverse events/effects